Developing innovative drugs for the treatment of liver diseases

Learn more about Tiziana

Tiziana Announces Closing of Offering and Resulting Total Voting Rights

16 March 2020

London, New York 16 March 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human...

Read more

Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 million

12 March 2020

Tiziana intends to use the net proceeds received from this Offering (i) to advance the clinical development of Foralumab for Crohn’s Disease and progressive multiple sclerosis, (ii) to expedite clinical development of TZLS-501 for coronavirus COVID-19, and (iii) for working capital and other general corporate purposes. Tiziana’s Ordinary Shares are admitted to trading on AIM, a market of the London Stock Exchange plc (“AIM”), under the symbol "TILS". The ADSs are listed for trading on the Nasdaq Global Market under the symbol “TLSA”.

Read more

Tiziana Life Sciences plc To Expedite Development of its Fully Human Anti-Interleukin-6-Receptor Monoclonal Antibody, a Potential Treatment of Certain Patients Infected with Coronavirus COVID-19

11 March 2020

Tiziana Life Sciences plc To Expedite Development of its Fully Human Anti-Interleukin-6-Receptor Monoclonal Antibody, a Potential Treatment of Certain Patients Infected with Coronavirus COVID-19

Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of reversing severe liver diseases, autoimmune and inflammatory diseases and optimizing health outcomes.

Learn more

Clinical Candidates

With several candidates in the clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.

Clinical development pipeline

Milciclib

Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma.

Learn more about Milciclib

Foralumab

Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of NASH, Crohn’ s Disease and a neurodegenerative indication.

Learn more about Foralumab

Pre-Clinical Candidates

With several candidates being prepared for clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.

Anti IL-6r (TZLS-501)

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6. This asset was in-licensed from Novimmune in January 2017.

Learn more about Anti IL-6r

StemPrintER™

StemPrintER is a multi-gene signature assay intended for use as a diagnostic screen in patients with estrogen-receptor positive ER+/HER2 negative breast cancers.

Learn more about StemPrintER™

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab and Milciclib

Milciclib

We initiated a Phase 2a trial (CDKO-125a-010) of Milciclib safety and tolerability as a single therapy in sorafenib-resistant patients with HCC in the first half of 2017.

See more Milciclib clinical trials

Foralumab

Tiziana is currently conducting a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston.

See more Foralumab clinical trials

Tiziana Life Sciences is listed on NASDAQ and AIM